This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Transplantation				
Transplantation	Intercellular adhesion molecule-1 (ICAM-1; CD54)	<i>In vitro</i> , mouse and nonhuman primate studies suggest an anti-ICAM-1 antibody could help prevent transplant rejection. In diabetic, humanized mice, an anti-ICAM-1 antibody induced T cell tolerance toward the porcine islet antigens and prevented rejection of porcine islet xenografts compared with IgG control. In a nonhuman primate model of diabetes, the anti-ICAM-1 antibody induced T cell tolerance to porcine islet xenografts and prolonged graft survival when given in combination with regulators of B cell activation. Next steps could include additional studies to understand the mechanism of action. At least three companies have inhibitors of ICAM-1 in preclinical to Phase II testing to treat cancer and inflammatory indications.	Patent and licensing status unavailable	Jung, K.C. <i>et al. J. Exp. Med.</i> ; published online Oct. 24, 2011; doi:10.1084/jem.20111242 Contact: Seong Hoe Park, Seoul National University, Seoul, South Korea e-mail: pshoe@snu.ac.kr
SciBX 4(45); doi:10.1038/scibx.2011.1278 Published online Nov. 17, 2011				